RESUMO
OBJECTIVE: The correlation between treatment-emergent adverse events (TEAE) and antiseizure medication (ASM) drug load is a controversial topic. Previous studies used daily defined dosage (DDD) to measure drug load. We aim to assess if ASM adjusted to body weight and plasma levels were associated with TEAE. METHODS: We analyzed clinical visits of a trial on therapeutic drug monitoring in outpatients with epilepsy. TEAE, treatment, and its changes, as well as ASM plasma levels, were recorded at each visit. Each medication level was stratified according to its position in relation to its proposed reference range (below, in the lower half, upper half, or above). RESULTS: We analyzed 424 visits (151 participants). Treatment-emergent adverse events were reported in 84 (20%) visits. There was no significant difference when comparing visits with TEAE with those without TEAE in terms of ASM drug load (calculated with DDD), corrected for body weight, their changes since the last visit, as well as summed plasma levels compared to reference ranges. SIGNIFICANCE: Actual drug load seems not to represent a major determinant of TEAE recorded during routine visits, even when accounting thoroughly for the patient's exposure to the treatment. The use of structured questionnaires and neuropsychometric tests may assess more accurately the potential consequences of drug loads.
Assuntos
Epilepsia , Humanos , Peso Corporal , Epilepsia/tratamento farmacológico , Ensaios Clínicos como AssuntoRESUMO
Pain is one of the main factors assessed in most of the scores used to measure activity in rheumatoid arthritis (RA) and spondylo arthritis (SpA). However, the experience of pain is complex, subjective and influenced by many factors. Fibromyalgia (FM) is present in 16-38% of patients with inflammatory rheumatic diseases (IRD) and has been shown to significantly increase indices of disease activity, often preventing an adequate response to immunosuppressive treatments. Recognition of secondary FM is important to avoid overtreatment. This article explores the relationship between FM and IRD, and how to optimise the assessment and treatment of one in the presence of the other.
La douleur est l'un des principaux facteurs évalués dans la plupart des scores utilisés pour mesurer l'activité de la polyarthrite rhumatoïde (PR) et des spondylarthrites (SpA). Cependant, l'expérience de la douleur est complexe, subjective et influencée par de nombreux facteurs. La fibromyalgie (FM) est présente chez 16 à 38 % des patients atteints de maladies rhumatismales inflammatoires (MRI) et il a été démontré qu'elle augmente de manière significative les indices d'activité de la maladie, empêchant souvent une réponse adéquate aux traitements immunosuppresseurs. La reconnaissance de la FM secondaire est importante pour éviter le surtraitement. Cet article explore la relation entre la FM et les MRI, et comment optimiser l'évaluation et le traitement de l'une en présence de l'autre.
Assuntos
Artrite Reumatoide , Fibromialgia , Espondilartrite , Artrite Reumatoide/complicações , Artrite Reumatoide/diagnóstico , Fibromialgia/complicações , Fibromialgia/diagnóstico , Fibromialgia/epidemiologia , Humanos , Dor/complicações , Medição da Dor , Espondilartrite/complicações , Espondilartrite/diagnósticoRESUMO
Chronic musculoskeletal pain syndromes, including fibromyalgia, are often resistant to conventional medications and invasive therapies. Central hypersensitization, neurotransmitter dysregulation, and autonomic nervous system abnormalities are key pathomechanisms, frequently resulting in widespread pain and a variety of psychosomatic symptoms. Virtual Reality (VR) applications have demonstrated effectiveness in reducing pain, both during and after interventions, and in chronic conditions such as fibromyalgia and back pain. The proposed mechanisms behind VR's effectiveness include distraction and immersion, coupled with cognitive behavioral therapy, which promote neuroplasticity and alter pain perceptions. Functional MRI studies have shown the impact of VR interventions on specific brain regions. Advances in hardware and software, potentially combined with treatments like biofeedback, could enhance VR's role in managing chronic pain. Currently, VR for musculoskeletal pain syndromes is primarily used within multimodal programs, but it is also available for home use as a standalone health application. Future research should focus on the 'drug-like' effects of VR, requiring controlled trials with comparable study populations and appropriate sham interventions.
RESUMO
BACKGROUND: Persistent fibromyalgia-like symptoms have been increasingly reported following viral infections, including SARS-CoV-2. About 30% of patients with post-COVID-19 syndrome fulfill the fibromyalgia criteria. This complex condition presents significant challenges in terms of self-management. Digital health interventions offer a viable means to assist patients in managing their health conditions. However, the challenge of ensuring their widespread adoption and adherence persists. This study responds to this need by developing a patient-centered digital health management app, incorporating patient preferences to enhance usability and effectiveness, ultimately aiming to improve patient outcomes and quality of life. OBJECTIVE: This research aims to develop a digital health self-management app specifically for patients experiencing postviral fibromyalgia-like symptoms. By prioritizing patient preferences and engagement through the app's design and functionality, the study intends to facilitate better self-management practices and improve adherence. METHODS: Using an exploratory study design, the research used patient preference surveys and usability testing as primary tools to inform the development process of the digital health solution. We gathered and analyzed patients' expectations regarding design features, content, and usability to steer the iterative app development. RESULTS: The study uncovered crucial insights from patient surveys and usability testing, which influenced the app's design and functionality. Key findings included a preference for a symptom list over an automated chatbot, a desire to report on a moderate range of symptoms and activities, and the importance of an intuitive onboarding process. While usability testing identified some challenges in the onboarding process, it also confirmed the importance of aligning the app with patient needs to enhance engagement and satisfaction. CONCLUSIONS: Incorporating patient feedback has been a significant factor in the development of the digital health app. Challenges encountered with user onboarding during usability testing have highlighted the importance of this process for user adoption. The study acknowledges the role of patient input in developing digital health technologies and suggests further research to improve onboarding procedures, aiming to enhance patient engagement and their ability to manage digital health resources effectively. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/32193.